8-K: Telomir Pharmaceuticals Appoints Fractional CFO

Telomir Pharmaceuticals has appointed Andriy Mushak as its new fractional Chief Financial Officer, effective June 6, 2026.

Summary

• Alan Weichselbaum will step down as Chief Financial Officer of Telomir Pharmaceuticals, effective June 6, 2026.
• Andriy Mushak, a CPA and partner at LMAM Consulting Group, LLC, has been appointed as the new fractional Chief Financial Officer.
• The appointment is part of a consulting agreement where the company will pay $6,000 per month for financial leadership services.
• The role includes oversight of SEC reporting, audit readiness, financial modeling, and capital-markets support.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update; while the appointment of an experienced CPA is positive, the move to a fractional CFO role is a standard operational change for a company of this size.

Positives

• The transition is amicable, with no reported disagreements regarding company operations, policies, or practices.
• The new appointee, Andriy Mushak, brings over 20 years of experience in SEC reporting and financial statement audits.
• The fractional model provides cost-effective access to senior financial expertise at a fixed monthly rate of $6,000.

Negatives

• The departure of a full-time CFO in favor of a fractional arrangement may signal a shift in administrative structure or cost-cutting measures.

Risks

• Reliance on a fractional CFO may limit the depth of internal financial oversight compared to a full-time executive.
• Potential for conflicts of interest as the consultant maintains other clients in the life sciences and biotechnology sectors.
• The company remains responsible for all internal controls and financial disclosures, placing significant reliance on the consultant's advisory accuracy.

Future Outlook

The company intends to utilize the fractional CFO to strengthen its capital-markets readiness, maintain rigorous financial discipline, and ensure timely SEC compliance.

Management Comments

• The departure of Mr. Weichselbaum was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

Industry Context

StockSavvy.ai notes that the shift toward fractional executive leadership is an increasing trend among emerging growth biotech companies looking to balance high-level financial expertise with operational cost efficiency.

Comparison to Industry Standards

• The use of a fractional CFO is common among small-cap and emerging growth companies listed on Nasdaq.
• The compensation structure is consistent with market rates for outsourced financial advisory services for companies of similar size.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may view the change as a cost-saving measure or a strategic pivot toward more specialized, project-based financial leadership.

Next Steps

• Integration of Andriy Mushak into the company's financial reporting and audit processes.
• Ongoing oversight of SEC compliance and capital-markets strategy.

Key Dates

Recommendation

The filing represents a routine administrative change in executive leadership. While the new CFO has relevant experience, the transition to a fractional role does not fundamentally alter the company's investment thesis or financial trajectory at this time.

Keywords

Telomir Pharmaceuticals, TELO, Fractional CFO, SEC Reporting, Corporate Governance, Executive Appointment